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Background: To explore the relationship between CYP4F2 gene polymorphism and coronary heart disease (CHD)
in a Chinese Han population.
Methods: We selected 440 CHD patients and 440 control subjects to perform a case - control study. Four SNPs
(rs2108622, rs3093100, rs3093105 and rs3093135) in CYP4F2 gene were genotyped using polymerase chain reaction -
restriction fragment length polymorphism (PCR - RFLP) methods. The genotype and haplotype distributions were
compared between the case and the control group.
Results: We found both rs2108622 and rs3093105 in CYP4F2 gene were associated with the risk for CHD (P <0.01).
Haplotype analysis indicated that GGGT haplotype consisted by rs2108622-rs3093100-rs3093105-rs3093135 was
associated with CHD risk (OR = 4.367, 95% CI: 2.241 ~ 8.510; P < 0.001), but GGTA haplotype was associated with
decreased risk for CHD (OR = 0.450, 95% CI: 0.111 ~ 0.777; P <0.001).
Conclusion: CYP4F2 gene polymorphisms were associated with the risk of CHD in Chinese population.
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Coronary heart disease (CHD) is one of the most common
diseases to influence the human health. Previous study in-
dicated that the morbidity and mortality of CHD are very
high [1]. CHD was a complex polygenic disease resulting
from the interaction between genetic variations and envir-
onmental factors [2]. Although the exact genetic mechan-
ism is unclear, some new susceptibility gene of the CHD
have been reported recently, such as apolipoprotein (Apo)
E [3], CYP8A1 [4], C5L2 [5], and interleukin (IL)-1 [6].
Grammer et al. [3] analyzed the association between the
apo E genotype, CRP and angiographic coronary artery
disease (CAD). The concentration of CRP was similar in
patients with stable CAD and in controls, but increased* Correspondence: wangxk_008@126.com
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In models adjusting for the main confounding variables,
the ɛ2 allele was associated with a lower prevalence of
angiographic CAD. Therefore, the authors concluded
that the apo E genotype is associated with circulating
CRP and risk for CAD. Xie et al. [4] performed a case–
control study in a Chinese population and investigated
the roles of polymorphisms in the CYP8A1 gene in
CHD susceptibility. The authors found that CYP8A1
genetic polymorphisms are associated with CHD in
Chinese population. Zheng et al. [5] identified a novel
SNP-901G > A in C5L2 gene and found this SNP may
be a genetic maker of CHD in the Han and Uygur popu-
lation. Zhou et al. performed a meta-analysis of 13 inde-
pendent case–control studies and suggested that there
were no associations between IL-1 gene cluster polymor-
phisms and CHD. However, these genes have not been
verified in different ethnicities.
20 - hydroxy eicosane arachidonic acid (20-HETE) is
a metabolite of arachidonic acid (AA) produced in theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Primers and PCR conditions of four SNPs
SNPs Primers Endonuclease Tm (°C)
rs2108622 F: 5’-ATCAACCCGTTCCCACCT-3’ Pvu II 55
R: 5’-ACATTGTGCTCCCAGACG-3’
rs3093100 F: 5’-AGTGCTTACTAGGGAACTGGAG-3’ Apa I 54
R: 5’-AAGGATTCAATGCAGGCCTGGA-3’
rs3093105 F: 5’-AGCCCTCCCTGCTCTACCT-3’ Eae I 56
R:5’-CCCACTCCCTAAGCCTCGT-3’;
rs3093135 F : 5’-GGCAGGCAGTCATCCACA-3’ Hinf I 52
R: 5’-CCAAACAGGCCCTCACAT-3’
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potent actions on renal tubular and vascular function
including: vasoconstriction secondary to inhibition of
large conductance Ca2+-activated K+ channels in vascu-
lar smooth muscle cells and inhibition of Cl− transport
in the thick ascending loop of Henle [7,8]. 20-HETE has
also been implicated as a second messenger mediating
the inhibitory effects of dopamine, PTH, and angioten-
sin II on Na+-K+-ATPase activity and sodium transport
in the proximal tubule [9,10]. Some studies have sug-
gested that increased levels of 20-HETE in the renal
vasculature may underlie the development of hyperten-
sion [11], and, animal experiments showed that 20-HETE
can cause vasospasm after hemorrhagic stroke, and it par-
ticipates in the incidence and the development process of
CHD and cerebral infarction [12]. In the rat models with
myocardial infarction, when the 20-HETE synthesis was
suppressed, infarct size can be reduced [12]. In hyperten-
sive mice models, the increased 20-HETE production can
lead to oxidative stress and endothelial cell damage, which
results in the increased incidence of CHD [13].
CYP4F2 is the major synthase which can catalyze the
arachidonic acid to generate 20-HETE. Recently, Stec
et al. demonstrated that a SNP (rs2108622, V433M) in
CYP4F2 gene may cause 20-HETE reduction from arachi-
donic acid [14]. Fava et al. [15] studied the elderly patients
with cerebral infarction in Sweden, and they found that
V433M mutation in CYP4F2 gene was associated with
cerebral infarction in male patients. A study [16] based
on Japanese population found that G allele frequency
of rs2108622 in male patients was higher than that in
the controls. TCG haplotypes composed by rs3093135-
rs1558139-rs2108622 is a risk factor for cerebral infarc-
tion in men [17]. In addition, Fava et al. [18] also found
CYP4F2 M433 carriers had significantly higher levels of
waist, triglycerides, BP and a composite sum of MetS phe-
notypes (MetS score) beside lower HDL-cholesterol re-
spect to V-homozygotes. However, the relation between
CYP4F2 genetic polymorphisms with CHD in Chinese
population remains unclear. In the present study, we
utilized a case–control study to reveal the relationship
between CYP4F2 gene polymorphism and CHD.
Materials and methods
Ethics
The present study has been performed with the approval
of the ethics committee of The Third Military Medical
University and is in compliance with the Helsinki Declar-
ation. The informed consents of the study were collected
from all the candidate subjects.
Subjects
A total of 440 hospitalized CHD patients in the Depart-
ment of Cardiology, Daping Hospital, The Third MilitaryMedical University were enrolled from September 2011 to
April 2013. All these CHD patients were unrelated Han
Chinese people. The patients were diagnosed CHD ac-
cording to the criteria which was described previously
[19]. Briefly, CHD was defined as the presence of stenosis
of more than 50% luminal diameter in at least one signifi-
cant coronary artery on coronary angiography. Patients
with ascertained congenital hypercoagulation, with proven
disease limiting life expectance or with cocaine abuse were
excluded.
During the same period, 440 persons in medical center
of the same hospital were selected as the control group.
All these control subjects were Han people whose age
and sex were matched with the patient group. The sub-
jects with cerebrovascular disease, neurological diseases,
kidney disease, blood disorders, cancer, peripheral vascular
disease, and autoimmune diseases were excluded from the
control group. These control subjects have no the history
of CHD and any symptom of CHD. The clinical char-
acteristics including age, gender, height, weight, blood
pressure, lipids profiles, fasting glucose, past medical
history, drug history, smoking history, and alcohol his-
tory were collected.DNA extraction
2 mL of fasting venous blood was taken from antecubital
vein and placed in EDTA-containing tubes. The genomic
DNA extraction kit (Promega Corporation, United States)
was used for DNA extraction from blood samples of the
subjects according to the kit’s protocol.SNPs selection
There are 740 SNPs for the human CYP4F2 gene listed
in the National Center for Biotechnology Information
SNP database (http://www.ncbi.nlm.nih.gov/SNP). We also
screened the data for the Tag SNPs on the International
HapMap Project website (http://www.hapmap.org/). We
searched tag SNP using Haploview 4.2 software in human
HapMap Project database with the following criteria:
r2 ≥ 0.8 and minimum gene frequency (MAF) ≥ 0.1. We


















































64 (14.5) 66 (15.0) 75 (17.0) 4.6 ± 1.5 1.5 ± 1.0 4.0 ± 0.9 1.4 ± 0.7 2.4 ± 0.9
P 0.322 0.053 <0.001 <0.001 <0.001 0.001 <0.001 <0.001 <0.001 <0.001 0.114 0.123
Note: BMI: Body Mass Index; SBP: Systolic Blood Pressure; DBP: Diastolic Blood pressure; GLU: Glucose; TG: Triglycerides; TC: Total cholesterol; HDL-C: High-density
Lipoprotein-C; LDL-C: Low-density Lipoprotein-C.
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and rs1558139) in CYP4F2 gene.
Genotyping
We utilized polymerase chain reaction - restriction frag-
ment length polymorphism (PCR - RFLP) to genotype
there 4 SNPs according to the protocol reported previ-
ously [20,21]. The primers were designed using the pri-
mer design software-primer 5.0. The primers were
shown in Table 1. To ensure the results to be verified,
we used sequenced genomic DNAs as positive controls
in our assays. Of the genotyped samples, 10% were du-
plicated and there was at least one positive and one
negative control per 96-well DNA plate in our assays.
The accuracy of the genotyping was determined by
genotype concordance between duplicate samples. We
obtained 100% concordance between the genotyped du-
plicate samples for each of the SNPs.
Statistical analysis
For each polymorphism, departure of the genotype
distribution from that expected from Hardy-Weinberg
equilibrium was assessed using the standard χ2 test or
Fisher’s exact test. Genotype frequencies in cases and
controls were compared by χ2 tests. The genotype-specific
risks were estimated as odds ratios (ORs). In all cases wild
type genotype served as a reference group. Based on the
genotype data of the genetic variations, we performed
linkage disequilibrium (LD) analysis and haplotype-Table 3 Distributions of CYP4F2 genotypes (N = 440)
SNPs Allels (1/2) Groups Genotypes (n, %)
1/1 1/2 2/2
rs2108622 A/G Case 34(0.077) 168(0.382) 238(0.541)
Control 46(0.105) 191(0.434) 203(0.461)
rs3093100 C/G Case 7(0.016) 94(0.214) 339(0.770)
Control 12(0.027) 97(0.220) 331(0.752)
rs3093105 T/G Case 22(0.050) 117(0.266) 301(0.684)
Control 10(0.023) 87(0.198) 343(0.780)
rs3093135 A/T Case: 12(0.027) 93(0.211) 335(0.761)
Control: 15(0.034) 101(0.230) 324(0.736)based case–control analysis, using the SHEsis software
(http://analysis2.bio-x.cn/myAnalysis.php). In the haplotype-
based case–control analysis, haplotypes with a frequency
of <0.03 were excluded. Statistical significance was estab-
lished at P <0.05. In the present study, we performed the
case–control study included 440 CHD patients and 440
control subjects. The estimated power is 83.3%.
Results
The characteristics of participants
There were no significant difference in the distribution of
age, BMI, HDL-C and LDL-C between the CHD group
and the control group. However, there were significant dif-
ferences in hypertension, diabetes, smoking history, DBP,
SBP and GLU, TG, TC concentration between CHD group
and control group (Table 2).
Hardy-Weinberg equilibrium
The genotype distribution in all SNPs were in line with
Hardy-Weinberg genetic equilibrium in both CHD group
and the control group (all P > 0.05, data not shown).
Genotype and allele frequencies
We found GG genotype frequency of rs2108622 were sig-
nificantly higher in the CHD patients than that in control
group (P <0.05). And the G allele frequency was also sig-
nificantly higher than that in control group (P = 0.011,
Table 3). TT genotype of rs3093105 was common in CHD
patients than that in control subjects (P = 0.003). And theP value Allele (n, %) OR (95% CI) P value
1 2
0.048 236(0.268) 644(0.732) 0.773(0.629 ~ 0.949) 0.011
283(0.322) 597(0.678)
0.482 108(0.123) 772(0.877) 0.877(0.664 ~ 1.158) 0.357
121(0.138) 759(0.863)
0.003 161(0.183) 719(0.817) 1.617(1.241 ~ 2.107) <0.001
107(0.122) 773(0.878)
0.654 117(0.133) 763(0.867) 0.876(0.670 ~ 1.147) 0.337
131(0.149) 749(0.851)
Figure 1 Genetic variation at human CYP4F2 gene. Using the SHEsis software, we calculated the Linkage disequilibrium (LD) value between
each SNP. A: LD value shown: |D’| × 100; |D’| colour scheme: |D’| <0.5: white; 0.5 < r 2 < 1: shades of Pink; |D’| = 1: red; B: LD value shown: r 2 × 100;
r 2 colour scheme: r 2 < 0.5: white; 0.5 < r 2 < 1: shades of grey; r 2 = 1: black.
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control group (P < 0.001, Table 3).Haplotype analyses
According to the results of linkage disequilibrium analysis
(As shown in Figure 1), we chose rs2108622-rs3093100-
rs3093105-rs3093135 to construct haplotypes using SHEsis
software. The results showed that, GGGT haplotype distri-
bution frequency in the CHD group was significantly
higher than that in the control group. Individuals carrying
GGGT Haplotype had 4.367 times increased risk of CHD
(OR = 4.367, 95% CI: 2.241 ~ 8.510; P < 0.001). However,
the GGTA frequency was lower in CHD patients than
that in the control subjects. Individuals carrying GGTA
Haplotype had 0.450 times decreased risk of CHD (OR =
0.450, 95% CI: 1.111 ~ 7.777; P < 0.001), (Table 4).Discussion
In this haplotype-based case–control study, we found
GGGT haplotype carriers have higher risk but GGTA
haplotype carriers have decreased risk for CHD in Han
Chinese population. To the best of our knowledge, this
is the first study to reveal the relation between CYP4F2
polymorphisms and CHD in Chinese Han population.Table 4 Haplotype distribution between case and control
Haplotypes CHD Control
A C T T 108.00(0.123) 121.00(0.137)
A G T T 128.00(0.145) 152.00(0.173)
G G G A 114.85(0.131) 86.11(0.098)
G G G T 46.14(0.052) 10.89(0.012)
G G T A 21.4(0.020) 44.89(0.051)The genetic variation is the molecular basis of human
genetic diversity. The T allele of CYP4F2 rs2108622 rep-
resents a missense mutation that results in the change
of valine 433 to methionine (V433M). This change in
the primary structure of CYP4F2 affects enzyme activity,
leading to changes in drug metabolism, physiology, and
pathophysiology. Cha et al. [22] through a genome-wide
association study identified rs2108622 as a genetic deter-
minant of warfarin responsiveness for Japanese. However,
no association was found between this SNP and CHD by a
genome-wide association study approach. CHD is caused
by the interaction between environmental and genetic
factors. In this study, an important human metabolic
enzyme P450 gene family member- CYP4F2 gene was se-
lected as the candidate gene to perform the case–control
study, and we found that rs2108622 and rs3093105 in
CYP4F2 gene was significantly associated with higher risk
for CHD. We also found GGGT haplotype consisting of
rs2108622-rs3093100-rs3093105-rs3093135 was the sus-
ceptibility haplotype of CHD. Our results were consistent
with the results reported by Fu et al. [17], but inconsistent
with results by Ward et al. [23] and Fava et al. [15]. Ward
et al. found that the A allele was a risk factor for hyperten-
sion. The other study by Fava et al. [15] found that the A
allele was a risk factor for IS. This difference may be dueP OR 95%CI
0.310 0.866 0.656 ~ 1.144
0.095 0.804 0.622 ~ 1.039
0.058 1.366 1.016 ~ 1.838
<0.001 4.367 2.241 ~ 8.510
<0.001 0.450 0.111 ~ 0.777
Yu et al. Lipids in Health and Disease 2014, 13:83 Page 5 of 5
http://www.lipidworld.com/content/13/1/83to different races, different methodologies and different
patient selection criteria.
Singh et al. [24] found that androgen-induced CYP4A8
expression reduced CYP2C23 expression and caused in-
creased production of 20-HETE, then the epoxyeicosa-
trienoic acid (EET) decreased to affect the contraction
of blood vessels. However, the exact mechanism of the
susceptibility for CHD remains unclear.
In addition, although an elevated level of LDL-C and a
decreased level of HDL-C in serum are independent risk
factors for CHD, we did not find the LDL-C level and
HDL-C level to be different between the CHD patients
and the control subjects. This phenomenon may be the
result from the treatment of decreased-cholesterol drugs
(e.g., simvastatin, lovastatin) in CHD patients.
Several limitations of the present study should be
noted. Firstly, these findings should be interpreted with
caution because the population was only from Chinese
population, this fact may reduce the possibility of con-
founding from ethnicity; Secondly, the present study is a
hospital based case–control study, the selection bias can-
not be avoidable and the subjects may not be representa-
tive of the general population; Finally, in the present
study, we did not detect the amount of 20-HETE associ-
ated with CYP4F2 polymorphisms.
Conclusion
In conclusion, this study showed that both rs2108622 and
rs3093105 in CYP4F2 gene were associated with CHD in
Han Chinese population.
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